BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

QT 5, Inc. Supplies Ten-Minute HIV Test For Evaluation By Department of Defense


10/19/2005 5:10:46 PM

WESTLAKE VILLAGE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- QT 5, Inc. (BULLETIN BOARD: QTFV) , manufacturer, distributor and marketers of biomedical diagnostics and NICOWater(TM), a Homeopathic Nicotinum Formula, today announced it has submitted their recently acquired ten-minute HIV1 and HIV2 qualitative diagnostic kit to the office of the Army's Surgeon General.

"Although our HIV test is still in Phase 3 of the FDA approval process; the word is out about the exciting potential of our entire patented diagnostic platform," said QT 5, Inc. CEO Timothy Owens. "In addition to impressive private, institutional and local government markets, the United States Federal Government represents the single largest user base for QT 5 diagnostics. It is no mistake that all of our medical, scientific and regulatory advisors are widely recognized and well respected for their influence in the advancement of the biomedical sciences. As a result of our preliminary market research, QT 5 leadership has been actively presenting our products to many high level decision makers within the Federal Government. This most recent opportunity was in response to a written request from U.S. Army's Purchasing Review Dept."

About QT 5, Inc.

QT 5, Inc. is a Delaware corporation formed in April 1999 as a manufacturer, distributor and marketer of biomedical testing and Homeopathic products. QT 5, Inc. currently manufactures and markets NICOWater, its breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the symptoms of tobacco cravings. QT 5, Inc. continues to do research and development regarding future products for lifestyle enhancements. QT 5, Inc. is headquartered in Westlake Village, California. For more information on the Company please visit: http://www.qt5inc.com/. NICOWater(TM) is a Homeopathic Drug product that is sold under the FDA's Compliance Policy Guide Conditions Under Which Homeopathic Drugs May Be Marketed.

This press release contains forward-looking statements that involve risks, uncertainties and assumptions that, if they never materialize or prove incorrect, could cause the results of QT 5, Inc. to differ materially from those expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including any projections of earnings, revenue, or other financial items, any statements of the plans, strategies, and objectives of management for future operations, any statements concerning proposed new products, services or developments, any statements regarding future economic conditions or performance, statements of belief and any statements of assumptions underlying any of the foregoing. These statements are based on expectations as of the date of this press release. Actual results may differ materially from those projected because of a number of risks and uncertainties, including those detailed from time to time in the reports filed by QT 5, Inc. with the Securities and Exchange Commission. QT 5, Inc. assumes no obligation and does not intend to update these forward-looking statements.

QT 5, Inc.

CONTACT: Steve Reder, President of QT 5, Inc., +1-818-338-1510, orsreder@qt5inc.com; or Media - Peter Berk, ext. 205, peter@crierpr.com, or J.P.Lincoln, ext. 201, jp@crierpr.com, both of Crier Communications,+1-310-274-1072, for QT 5, Inc.



Read at BioSpace.com

   
HIV/AIDS

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES